The Role of Adipocytokines in Coronary Atherosclerosis

Current Atherosclerosis Reports

Volumn 19, Issue 2, 2017, Pages

  Liberale, Luca ^a   Bonaventura, Aldo ^a   Vecchiè, Alessandra ^a   Matteo, Casula ^a   Dallegri, Franco ^a,b   Montecucco, Fabrizio ^a,b,c   Carbone, Federico ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Adipocytokines; Adipose tissue; Atherosclerosis; Cardiovascular risk; Coronary arteries; Perivascular adipose tissue

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; RESISTIN;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; REVIEW; ANIMAL; ATHEROSCLEROSIS; CORONARY DISEASE; DISEASE COURSE; METABOLISM; RISK FACTOR;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; ATHEROSCLEROSIS; CORONARY DISEASE; DISEASE PROGRESSION; HUMANS; RISK FACTORS;

EID: 85011954502     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-017-0644-3     Document Type: Review

References (111)

1. Carbone F, Mach F, Montecucco F. The role of adipocytokines in atherogenesis and atheroprogression. Curr Drug Targets. 2015;16(4):295–320.
2. Murano I, Barbatelli G, Parisani V, et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res. 2008;49(7):1562–8.
3. Chatterjee TK, Stoll LL, Denning GM, et al. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res. 2009;104(4):541–9.
4. Tsioufis C, Dimitriadis K, Selima M, et al. Low-grade inflammation and hypoadiponectinaemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients. Eur Heart J. 2007;28(9):1162–9.
5. Kim DH, Kim C, Ding EL, Townsend MK, Lipsitz LA. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27–32.
6. Fesus G, Dubrovska G, Gorzelniak K, et al. Adiponectin is a novel humoral vasodilator. Cardiovasc Res. 2007;75(4):719–27.
7. Margaritis M, Antonopoulos AS, Digby J, et al. Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation. 2013;127(22):2209–21.
8. Gustafsson S, Lind L, Soderberg S, Zilmer M, Hulthe J, Ingelsson E. Oxidative stress and inflammatory markers in relation to circulating levels of adiponectin. Obesity (Silver Spring). 2013;21(7):1467–73.
9. Ouedraogo R, Gong Y, Berzins B, et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest. 2007;117(6):1718–26.
10. Zhao HY, Zhao M, Yi TN, Zhang J. Globular adiponectin protects human umbilical vein endothelial cells against apoptosis through adiponectin receptor 1/adenosine monophosphate-activated protein kinase pathway. Chin Med J (Engl). 2011;124(16):2540–7.
11. Chang J, Li Y, Huang Y, et al. Adiponectin prevents diabetic premature senescence of endothelial progenitor cells and promotes endothelial repair by suppressing the p38 MAP kinase/p16INK4A signaling pathway. Diabetes. 2010;59(11):2949–59.
12. Shimizu Y, Nagaya N, Teranishi Y, et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun. 2003;310(3):830–5.
13. Zheng Q, Yuan Y, Yi W, et al. C1q/TNF-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/AMPK/eNOS/nitric oxide signaling pathway. Arterioscler Thromb Vasc Biol. 2011;31(11):2616–23.
14. Maruyama S, Shibata R, Kikuchi R, et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem. 2012;287(1):408–17.
15. Yang D, Liu Z, Zhang H, Luo Q. Ghrelin protects human pulmonary artery endothelial cells against hypoxia-induced injury via PI3-kinase/Akt. Peptides. 2013;42:112–7.
16. Akiyama H, Furukawa S, Wakisaka S, Maeda T. CTRP3/cartducin promotes proliferation and migration of endothelial cells. Mol Cell Biochem. 2007;304(1–2):243–8.
17. Phalitakul S, Okada M, Hara Y, Yamawaki H. Vaspin prevents methylglyoxal-induced apoptosis in human vascular endothelial cells by inhibiting reactive oxygen species generation. Acta Physiol (Oxf). 2013;209(3):212–9.
18. •• Miyabe M, Ohashi K, Shibata R, et al. Muscle-derived follistatin-like 1 functions to reduce neointimal formation after vascular injury. Cardiovasc Res. 2014;103(1):111–20. The highlight is due to the high technical merit of this study.
19. Gonzalez M, Lind L, Soderberg S. Leptin and endothelial function in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis. 2013;228(2):485–90.
20. Yoo HJ, Choi HY, Yang SJ, et al. Circulating chemerin level is independently correlated with arterial stiffness. J Atheroscler Thromb. 2012;19(1):59–66. discussion 67–58.
21. Fang C, Lei J, Zhou SX, Zhang YL, Yuan GY, Wang JF. Association of higher resistin levels with inflammatory activation and endothelial dysfunction in patients with essential hypertension. Chin Med J (Engl). 2013;126(4):646–9.
22. Payne GA, Tune JD, Knudson JD. Leptin-induced endothelial dysfunction: a target for therapeutic interventions. Curr Pharm Des. 2014;20(4):603–8.
23. Chen C, Jiang J, Lu JM, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 2010;299(1):H193–201.
24. Landgraf K, Friebe D, Ullrich T, et al. Chemerin as a mediator between obesity and vascular inflammation in children. J Clin Endocrinol Metab. 2012;97(4):E556–64.
25. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78(2):356–65.
26. Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 2008;1783(5):886–95.
27. Cirillo P, Di Palma V, Maresca F, et al. The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: another piece in the adipokines puzzle. Thromb Res. 2012;130(3):403–8.
28. Park SE, Kim DH, Lee JH, et al. Retinol-binding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis. 2009;204(1):23–5.
29. Aragones G, Ferre R, Lazaro I, et al. Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis. 2010;213(1):329–31.
30. Song E, Fan P, Huang B, et al. Deamidated lipocalin-2 induces endothelial dysfunction and hypertension in dietary obese mice. J Am Heart Assoc. 2014;3(2), e000837.
31. Lu Y, Zhu X, Liang GX, et al. Apelin-APJ induces ICAM-1, VCAM-1 and MCP-1 expression via NF-kappaB/JNK signal pathway in human umbilical vein endothelial cells. Amino Acids. 2012;43(5):2125–36.
32. Hashimoto T, Kihara M, Imai N, et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol. 2007;171(5):1705–12.
33. Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008;118(10):3343–54.
34. Carbone F, Mach F, Montecucco F. Update on the role of neutrophils in atherosclerotic plaque vulnerability. Curr Drug Targets. 2015;16(4):321–33.
35. Liberale L, Dallegri F, Montecucco F, Carbone F. Pathophysiological relevance of macrophage subsets in atherogenesis. Thromb Haemost 2016; 117(1).
36. Tomizawa A, Hattori Y, Kasai K, Nakano Y. Adiponectin induces NF-kappaB activation that leads to suppression of cytokine-induced NF-kappaB activation in vascular endothelial cells: globular adiponectin vs. high molecular weight adiponectin. Diab Vasc Dis Res. 2008;5(2):123–7.
37. Jenke A, Wilk S, Poller W, et al. Adiponectin protects against Toll-like receptor 4-mediated cardiac inflammation and injury. Cardiovasc Res. 2013;99(3):422–31.
38. Lovren F, Pan Y, Quan A, et al. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol. 2010;299(3):H656–63.
39. Wang M, Wang D, Zhang Y, Wang X, Liu Y, Xia M. Adiponectin increases macrophages cholesterol efflux and suppresses foam cell formation in patients with type 2 diabetes mellitus. Atherosclerosis. 2013;229(1):62–70.
40. Hulsmans M, Geeraert B, Arnould T, Tsatsanis C, Holvoet P. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression. PLoS One. 2013;8(4), e62253.
41. Demers A, Caron V, Rodrigue-Way A, Wahli W, Ong H, Tremblay A. A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages. PLoS One. 2009;4(11), e7728.
42. Yao F, Lv YC, Zhang M, et al. Apelin-13 impedes foam cell formation by activating Class III PI3K/Beclin-1-mediated autophagic pathway. Biochem Biophys Res Commun. 2015;466(4):637–43.
43. Hiramatsu-Ito M, Shibata R, Ohashi K, et al. Omentin attenuates atherosclerotic lesion formation in apolipoprotein E-deficient mice. Cardiovasc Res. 2016;110(1):107–17.
44. Dib LH, Ortega MT, Fleming SD, Chapes SK, Melgarejo T. Bone marrow leptin signaling mediates obesity-associated adipose tissue inflammation in male mice. Endocrinology. 2014;155(1):40–6.
45. Cho Y, Lee SE, Lee HC, et al. Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J Am Coll Cardiol. 2011;57(1):99–109.
46. Gonzalvo-Feo S, Del Prete A, Pruenster M, et al. Endothelial cell-derived chemerin promotes dendritic cell transmigration. J Immunol. 2014;192(5):2366–73.
47. Yun MR, Seo JM, Park HY. Visfatin contributes to the differentiation of monocytes into macrophages through the differential regulation of inflammatory cytokines in THP-1 cells. Cell Signal. 2014;26(4):705–15.
48. Halvorsen B, Espeland MZ, Andersen GO, et al. Increased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages. Atherosclerosis. 2015;243(1):204–10.
49. Wu G, Li H, Zhou M, et al. Mechanism and clinical evidence of lipocalin-2 and adipocyte fatty acid-binding protein linking obesity and atherosclerosis. Diabetes Metab Res Rev. 2014;30(6):447–56.
50. Law IK, Xu A, Lam KS, et al. Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity. Diabetes. 2010;59(4):872–82.
51. te Boekhorst BC, Bovens SM, Hellings WE, et al. Molecular MRI of murine atherosclerotic plaque targeting NGAL: a protein associated with unstable human plaque characteristics. Cardiovasc Res. 2011;89(3):680–8.
52. Hui X, Li H, Zhou Z, et al. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J Biol Chem. 2010;285(14):10273–80.
53. Furuhashi M, Tuncman G, Gorgun CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007;447(7147):959–65.
54. Rhee EJ, Lee WY, Park CY, et al. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol. 2009;160(2):165–72.
55. Mohanta SK, Yin C, Peng L, et al. Artery tertiary lymphoid organs contribute to innate and adaptive immune responses in advanced mouse atherosclerosis. Circ Res. 2014;114(11):1772–87.
56. Wilk S, Scheibenbogen C, Bauer S, et al. Adiponectin is a negative regulator of antigen-activated T cells. Eur J Immunol. 2011;41(8):2323–32.
57. Tsang JY, Li D, Ho D, et al. Novel immunomodulatory effects of adiponectin on dendritic cell functions. Int Immunopharmacol. 2011;11(5):604–9.
58. Souza-Moreira L, Delgado-Maroto V, Morell M, O’Valle F, Del Moral RG, Gonzalez-Rey E. Therapeutic effect of ghrelin in experimental autoimmune encephalomyelitis by inhibiting antigen-specific Th1/Th17 responses and inducing regulatory T cells. Brain Behav Immun. 2013;30:54–60.
59. Taleb S, Herbin O, Ait-Oufella H, et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(12):2691–8.
60. Pittelli M, Cavone L, Lapucci A, et al. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes. Immunol Cell Biol. 2014;92(2):191–9.
61. Sawada T, Shite J, Shinke T, et al. Low plasma adiponectin levels are associated with presence of thin-cap fibroatheroma in men with stable coronary artery disease. Int J Cardiol. 2010;142(3):250–6.
62. Moroi M, Akter S, Nakazato R, et al. Lower ratio of high-molecular-weight adiponectin level to total may be associated with coronary high-risk plaque. BMC Res Notes. 2013;6:83.
63. Luo S, Lei H, Liu Q. Correlation between serum adiponectin and risk factors in patients with coronary artery disease. Clin Lab. 2013;59(1–2):121–6.
64. Mittal A, Gupta MD, Meennahalli Palleda G, Vyas A, Tyagi S. Relationship of plasma adiponectin levels with acute coronary syndromes and coronary lesion severity in north Indian population. ISRN Cardiol. 2013;2013:854815.
65. Ji Q, Lin Y, Liang Z, et al. Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris. Cardiovasc Diabetol. 2014;13:145.
66. • Liu G, Ding M, Chiuve SE, et al. Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with Type 2 diabetes: a 22-year prospective study. Arterioscler Thromb Vasc Biol. 2016. The highlight is due to the long-term follow-up.
67. Li HL, Peng WH, Cui ST, et al. Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris. Clin Chem Lab Med. 2011;49(9):1547–54.
68. Zhang B, Peng W, Li H, et al. Plasma vaspin concentrations are decreased in acute coronary syndrome, but unchanged in patients without coronary lesions. Clin Biochem. 2013;46(15):1520–5.
69. Zhang B, Peng W, Wang K, Li H, Xu Y. Vaspin as a prognostic marker in patients with acute myocardial infarction. Heart Lung Circ. 2016;25(3):257–64.
70. Weir RA, Chong KS, Dalzell JR, et al. Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail. 2009;11(6):551–8.
71. Kadoglou NP, Lampropoulos S, Kapelouzou A, et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease—KOZANI STUDY. Transl Res. 2010;155(5):238–46.
72. Kuklinska AM, Sobkowicz B, Sawicki R, et al. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart Vessels. 2010;25(5):363–7.
73. Zhou Y, Wang Y, Qiao S. Apelin: a potential marker of coronary artery stenosis and atherosclerotic plaque stability in ACS patients. Int Heart J. 2014;55(3):204–12.
74. Zhang M, Fang W, Yuan F, et al. Plasma ghrelin levels are closely associated with stenosis severity and morphology of angiographically-detected coronary atherosclerosis in patients with coronary artery disease. Int J Cardiol. 2011;151(1):122–3.
75. Aronis KN, Moreno M, Polyzos SA, et al. Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events. Int J Obes (Lond). 2015;39(1):156–61.
76. Deng W. Association of serum irisin concentrations with presence and severity of coronary artery disease. Med Sci Monit. 2016;22:4193–7.
77. Shang FJ, Wang JP, Liu XT, et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome. Biomarkers. 2011;16(8):657–62.
78. Shibata R, Ouchi N, Kikuchi R, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011;219(2):811–4.
79. Saely CH, Leiherer A, Muendlein A, et al. High plasma omentin predicts cardiovascular events independently from the presence and extent of angiographically determined atherosclerosis. Atherosclerosis. 2016;244:38–43.
80. Menzel J, di Giuseppe R, Biemann R, et al. Omentin-1 and risk of myocardial infarction and stroke: results from the EPIC-Potsdam cohort study. Atherosclerosis. 2016;251:415–21.
81. Nguyen PA, Heggermont WA, Vanhaverbeke M, et al. Leptin-adiponectin ratio in pre-diabetic patients undergoing percutaneous coronary intervention. Acta Cardiol. 2015;70(6):640–6.
82. Caselli C, De Graaf MA, Lorenzoni V, et al. HDL cholesterol, leptin and interleukin-6 predict high risk coronary anatomy assessed by CT angiography in patients with stable chest pain. Atherosclerosis. 2015;241(1):55–61.
83. Bickel C, Schnabel RB, Zeller T, et al. Predictors of leptin concentration and association with cardiovascular risk in patients with coronary artery disease: results from the AtheroGene study. Biomarkers. 2016:1–9.
84. Wang H, Chen DY, Cao J, He ZY, Zhu BP, Long M. High serum resistin level may be an indicator of the severity of coronary disease in acute coronary syndrome. Chin Med Sci J. 2009;24(3):161–6.
85. Singh P, Sridhar MG, Rajappa M, Balachander J, Kadhiravan T. Adiponectin-resistin index and its strong association with acute coronary syndrome in South Indian men. Inflamm Res. 2014;63(11):961–8.
86. Joksic J, Sopic M, Spasojevic-Kalimanovska V, Kalimanovska-Ostric D, Andjelkovic K, Jelic-Ivanovic Z. Circulating resistin protein and mRNA concentrations and clinical severity of coronary artery disease. Biochem Med (Zagreb). 2015;25(2):242–51.
87. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009;71(2):202–7.
88. Lee YH, Lee SH, Jung ES, et al. Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1. Atherosclerosis. 2010;213(2):592–7.
89. Ni J, Ma X, Zhou M, et al. Serum lipocalin-2 levels positively correlate with coronary artery disease and metabolic syndrome. Cardiovasc Diabetol. 2013;12:176.
90. Reiser H, Klingenberg R, Hof D, et al. Circulating FABP4 is a prognostic biomarker in patients with acute coronary syndrome but not in asymptomatic individuals. Arterioscler Thromb Vasc Biol. 2015;35(8):1872–9.
91. Furuhashi M, Fuseya T, Murata M, et al. Local production of fatty acid-binding protein 4 in epicardial/perivascular fat and macrophages is linked to coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36(5):825–34.
92. Choi KM, Hwang SY, Hong HC, et al. Implications of C1q/TNF-related protein-3 (CTRP-3) and progranulin in patients with acute coronary syndrome and stable angina pectoris. Cardiovasc Diabetol. 2014;13:14.
93. Xiao Y, Liu L, Xu A, et al. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:72.
94. • Li Q, Zhang Y, Ding D, et al. Association between serum fibroblast growth factor 21 and mortality among patients with coronary artery disease. J Clin Endocrinol Metab 2016:jc20162308. The highlight is due to the large sample size of this study.
95. Yan Q, Zhang Y, Hong J, et al. The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine. 2012;41(2):281–8.
96. Aronis KN, Sahin-Efe A, Chamberland JP, Spiro 3rd A, Vokonas P, Mantzoros CS. Chemerin levels as predictor of acute coronary events: a case–control study nested within the veterans affairs normative aging study. Metabolism. 2014;63(6):760–6.
97. Dewey FE, Gusarova V, O’Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123–33.
98. Niinaga R, Yamamoto H, Yoshii M, et al. Marked elevation of serum M2BP-adiponectin complex in men with coronary artery disease. Atherosclerosis. 2016;253:70–4.
99. Soderberg S, Ahren B, Jansson JH, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999;246(4):409–18.
100. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007;115(8):972–80.
101. Lu LF, Wang CP, Yu TH, et al. Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction. Cytokine. 2012;57(1):74–80.
102. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr. 2009;22(12):1311–9. quiz 1417–1318.
103. •• Mahabadi AA, Massaro JM, Rosito GA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009;30(7):850–6. The highlight is due to the high technical merit.
104. Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005;365(9473):1817–20.
105. Mahabadi AA, Reinsch N, Lehmann N, et al. Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. Atherosclerosis. 2010;211(1):195–9.
106. Mazurek T, Opolski G. Pericoronary adipose tissue: a novel therapeutic target in obesity-related coronary atherosclerosis. J Am Coll Nutr. 2015;34(3):244–54.
107. • Maurovich-Horvat P, Kallianos K, Engel LC, et al. Relationship of thoracic fat depots with coronary atherosclerosis and circulating inflammatory biomarkers. Obesity (Silver Spring). 2015;23(6):1178–84. The highlight is due the technical merit.
108. Mazurek T, Kochman J, Kobylecka M, et al. Inflammatory activity of pericoronary adipose tissue may affect plaque composition in patients with acute coronary syndrome without persistent ST-segment elevation: preliminary results. Kardiol Pol. 2014;72(5):410–6.
109. Chatterjee TK, Aronow BJ, Tong WS, et al. Human coronary artery perivascular adipocytes overexpress genes responsible for regulating vascular morphology, inflammation, and hemostasis. Physiol Genomics. 2013;45(16):697–709.
110. Omar A, Chatterjee TK, Tang Y, Hui DY, Weintraub NL. Proinflammatory phenotype of perivascular adipocytes. Arterioscler Thromb Vasc Biol. 2014;34(8):1631–6.
111. Owen MK, Witzmann FA, McKenney ML, et al. Perivascular adipose tissue potentiates contraction of coronary vascular smooth muscle: influence of obesity. Circulation. 2013;128(1):9–18.